Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

This study has been completed.
Information provided by (Responsible Party):
Rajesh K. Garg, Brigham and Women's Hospital Identifier:
First received: July 26, 2011
Last updated: August 12, 2013
Last verified: August 2013
The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.

Condition Intervention
Insulin Resistance
Drug: Spironolactone
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

Resource links provided by NLM:

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Brachial artery vascular reactivity [ Time Frame: 6 weeks after respective treatments ]
    Change in brachial artery vasodilatation in response to ischemia will be compared between treatment and placebo groups.

Secondary Outcome Measures:
  • Renal plasma flow [ Time Frame: 6 weeks ]
    Change in renal plasma blood flow from baseline will be compared between the treatment and placebo groups.

  • Inflammatory markers [ Time Frame: 6 weeks ]
    TNF alpha and MCP-1 will be measured as markers of inflammation. Changes in TNF alpha and MCP-1 from baseline will be compared between the treatment and placebo groups.

  • Insulin resistance [ Time Frame: 6 weeks ]
    Change in insulin resistance from baseline will be compared between the treatment and placebo groups.

Enrollment: 32
Study Start Date: February 2009
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Spironolactone Drug: Spironolactone
50 mg daily for 6 weeks
Placebo Comparator: Placebo Drug: Placebo
Placebo once daily for 6 weeks


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-70 years
  2. Good health as evidenced by history and physical exam
  3. BMI: >30 kg/m2 and <45 kg/m2

Exclusion criteria:

  1. Medical illnesses other than treated hypothyroidism
  2. BP >135/85 or systolic BP <90 mm Hg
  3. Hepatic disease (transaminase > 3 times normal)
  4. Renal impairment (Creatinine clearance <60 ml/min)
  5. Baseline serum K >5.0 mmol/L
  6. History of drug or alcohol abuse
  7. Allergies to spironolactone
  8. Participation in any other concurrent clinical trial
  9. Women using oral contraceptives within the last 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01406015

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Rajesh K. Garg, Associate Physician, Brigham and Women's Hospital Identifier: NCT01406015     History of Changes
Other Study ID Numbers: 2009P-000311
Study First Received: July 26, 2011
Last Updated: August 12, 2013

Keywords provided by Brigham and Women's Hospital:
Insulin resistance
Mineralocorticoid receptor

Additional relevant MeSH terms:
Insulin Resistance
Nutrition Disorders
Body Weight
Signs and Symptoms
Glucose Metabolism Disorders
Metabolic Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents
Hormones processed this record on April 26, 2017